pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vosevi
drug
save

(sofosbuvir + velpatasvir + voxilaprevir)

Marketedupdated 3mo ago
by $GILD GILEAD SCIENCES, INC.
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 21, 2028
~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (32)

  • Dec 1, 2037patentUS 11338007*PED
  • Jun 1, 2037formulationUS 10912814
  • Jun 1, 2037formulationUS 11338007
  • Jul 30, 2034patentUS 11116783*PED
  • Jul 17, 2034compositionUS 9296782
  • Jan 30, 2034formulationUS 11116783
  • May 16, 2033patentUS 8575135*PED
  • May 16, 2033patentUS 8921341*PED
  • May 16, 2033patentUS 8940718*PED
  • Nov 16, 2032compositionUS 8575135
  • Nov 16, 2032compositionUS 8921341
  • Nov 16, 2032compositionUS 8940718
  • Nov 16, 2032compositionUS 9868745
  • Jun 11, 2031patentUS 8618076*PED4.8y
  • Mar 13, 2031patentUS 9284342*PED4.6y
  • Dec 11, 2030compositionUS 86180764.3y
  • Sep 13, 2030compositionUS 92843424.1y
  • Sep 26, 2029patentUS 7964580*PED3.1y
  • Sep 26, 2029patentUS 8633309*PED3.1y
  • Sep 26, 2029patentUS 8889159*PED3.1y
  • Mar 26, 2029compositionUS 79645802.6y
  • Mar 26, 2029compositionUS 86333092.6y
  • Mar 26, 2029compositionUS 88891592.6y
  • Sep 21, 2028patentUS 8334270*PED2.1y
  • Sep 21, 2028patentUS 8580765*PED2.1y
  • Sep 21, 2028patentUS 8735372*PED2.1y
  • Sep 21, 2028patentUS 9085573*PED2.1y
  • Mar 21, 2028compositionUS 83342701.6y
  • Mar 21, 2028compositionUS 85807651.6y
  • Mar 21, 2028compositionUS 87353721.6y
  • Mar 21, 2028method-of-use (U-2039)US 89570461.6y
  • Mar 21, 2028compositionUS 90855731.6y

News(0)

no news has mentioned this drug yet

brand
Vosevi
generic
(sofosbuvir + velpatasvir + voxilaprevir)
indication
Hepatitis C
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 49m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?